Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PATENT-1
- Sponsors Bayer; Bayer HealthCare
- 13 Nov 2023 Results of post-hoc analysis assessing COMPERA 2.0 to the PATENT 1& PATENT 2 studies of riociguat in patients with pulmonary arterial hypertension, presented at the American Heart Association Scientific Sessions 2023.
- 13 Nov 2023 Results of pooled post hoc analysis (n=741 from studies PATENT-1, PATENT PLUS, RESPITE, MOTION, REPLACE) assessing the impact of riociguat in patients with PAH and comorbidities presented at the American Heart Association Scientific Sessions 2023
- 28 Oct 2021 Results(n=396) from PATENT-1 and PATENT-2, investigating the effect of riociguat on REVEAL Lite 2 score, published in the Journal of Heart and Lung Transplantation